Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Description complète

Détails bibliographiques

Auteurs principaux:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2017-06-01
Collection:	Blood Advances
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!